NASDAQ: PMCB - PharmaCyte Biotech, Inc.

Rentabilität für sechs Monate: -30.89%
Dividendenrendite: 0.00%
Sektor: Healthcare

Aktionsplan PharmaCyte Biotech, Inc.

Erweiterter Zeitplan Einfaches Diagramm
Financial Markets by TradingView

Über das Unternehmen PharmaCyte Biotech, Inc.

PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer, as well as diabetes.

weitere details
The company is developing therapies for pancreatic and other solid cancerous tumors; a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes, which include encapsulated genetically modified insulin-producing cells; and therapies for cancer based on the constituents of the cannabis plant. It has a research agreement with the University of Technology, Sydney to create a version of melligen cells to treat diabetes. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.
Zur Vergleichsliste hinzufügen
Auf die Beobachtungsliste
Zum Portfolio hinzufügen
Preishinweis hinzufügen

IPO date 2010-09-17
ISIN US71715X2036
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://pharmacyte.com
Цена ао 1.49
Preisänderung pro Tag: -4.35% (1.38)
Preisänderung pro Woche: -16.46% (1.58)
Preisänderung pro Monat: -23.26% (1.72)
Preisänderung über 3 Monate: -15.92% (1.57)
Preisänderung über sechs Monate: -30.89% (1.91)
Preisänderung pro Jahr: -44.3% (2.37)
Preisänderung über 3 Jahre: -45.68% (2.43)
Preisänderung über 5 Jahre: +2 488.24% (0.051)
Preisänderung seit Jahresbeginn: -19.51% (1.64)
Alle Parameter

Unterschätzung

Name Bedeutung Grad
P/S 0 0
P/BV 0.514 10
P/E 60.86 1
EV/EBITDA -89.49 0
Gesamt: 3.63

Effizienz

Name Bedeutung Grad
ROA, % 0.5012 1
ROE, % 0.5949 1
Gesamt: 0.3333

Dividenden

Name Bedeutung Grad
Div yield, % 0 0
DSI 0 0
Gesamt: 0.0212

Pflicht

Name Bedeutung Grad
Debt/EBITDA 0 10
Gesamt: 10

Wachstumsimpuls

Name Bedeutung Grad
Rentabilität Revenue, % -98.14 0
Rentabilität Ebitda, % -108.78 0
Rentabilität EPS, % -1344.13 0
Gesamt: 0
Weitere Details

Institutionen Volumen Aktie, %
K2 Principal Fund, L.P. 304613 0.01
Geode Capital Management, LLC 215637 0.01
Vanguard Group Inc 171335 0.01
Equitec Proprietary Markets LLC 82727 0
Sabby Management, LLC 82373 0
Renaissance Technologies, LLC 38100 0
Dimensional Fund Advisors LP 29307 0
Blackrock Inc. 28769 0
Citadel Advisors Llc 28618 0
Schonfeld Strategic Advisors LLC 23200 0

ETFAktie, %Rentabilität für das Jahr, %Dividenden, %
Dimensional U.S. Targeted Value ETF 0.00013 26.01 1.93487
Dimensional U.S. Core Equity 2 ETF 0.00006 30.76 1.47098
028.391.7



Aufsicht Berufsbezeichnung Zahlung Geburtsjahr
Mr. Joshua N. Silverman Interim CEO, Interim President & Interim Chairman 197.92k 1970 (55 Jahre)
Mr. Carlos A. Trujillo CPA, CPA Chief Financial Officer 380k 1958 (67 Jahre)
Dr. Jose L. Iglesias M.D. Consulting Chief Medical Officer N/A 1957 (68 Jahre)
Dr. Hans-Peter Hammes Member of Medical & Scientific Advisory Board and Consultant N/A

Adresse: United States, Las Vegas. NV, 3960 Howard Hughes Parkway - in Google Maps öffnen, Öffnen Sie Yandex-Karten
Webseite: https://pharmacyte.com